ASC Biosciences, Inc. Signs Letter Of Intent With Stem Cell Development Fund LLC for Staged Funding in Support of … – PR Newswire (press release)
|
ASC Biosciences, Inc. Signs Letter Of Intent With Stem Cell Development Fund LLC for Staged Funding in Support of …
PR Newswire (press release) PALM DESERT, Calif., June 8, 2017 /PRNewswire/ — ASC Biosciences, Inc. (formerly Nevis Capital Corporation) (“ASC”) (OTC Pink Open Markets: ASCW) is pleased to announce it has enter into a Letter Of Intent (LOI) with Stem Cell Development Fund to … |
|
BRIEF-Medicenna’s Immunotherapy phase 2B trial underway using Brainlab drug delivery technology
Reuters OTTAWA, June 8 Canadian housing starts dipped in May as construction intentions fell in the major cities of Toronto and Vancouver, data from the Canada Mortgage and Housing Corporation showed on Thursday. |
|
BRIEF-Medicenna’s Immunotherapy phase 2B trial underway using …
Reuters WASHINGTON, June 8 As the United States battles a growing opioid abuse crisis, the Food and Drug Administration on Thursday asked Endo International Plc … |
Medical Xpress |
Stem cell treatment for lethal STAT1 gene mutation produces mixed results
Medical Xpress Researchers report the first-ever study assessing how patients with “gain of function” mutation of the STAT1 gene respond to stem cell transplantation. It involved 15 young patients from nine different countries, each suffering a range of complications … |
Medical Xpress |
Stem cell treatment for lethal STAT1 gene mutation produces mixed results
Medical Xpress Researchers report the first-ever study assessing how patients with “gain of function” mutation of the STAT1 gene respond to stem cell transplantation. It involved 15 young patients from nine different countries, each suffering a range of complications … |
Xconomy |
Harvard Biotech Spinout Lands $10M to Make Platelets From Stem Cells
Xconomy Karlsson’s startup aims to bring hospitals an alternative: platelets produced as needed from stem cells. Platelet BioGenesis, a spinout from Harvard University and Brigham and Women’s Hospital, now has $10 million from a Series A round of funding to … |
PharmaTimes |
Novartis’ CAR–T shows durable response in lymphoma patients
PharmaTimes Novartis’ closely-watched CTL019 has elicited a strong response in cancer patients taking the experimental CAR–T cell therapy in a mid-stage trial. Findings from an interim analysis of the multicentre Phase II JULIET study show a three-month overall … |